ロード中...
Long-term efficacy and safety of oral semaglutide and the effect of switching from sitagliptin to oral semaglutide in patients with type 2 diabetes: a 52-week, randomized, open-label extension of the PIONEER 7 trial
INTRODUCTION: The PIONEER 7 trial demonstrated superior glycemic control and weight loss with once-daily oral semaglutide with flexible dose adjustment versus sitagliptin 100 mg in type 2 diabetes. This 52-week extension evaluated long-term oral semaglutide treatment and switching from sitagliptin t...
保存先:
| 出版年: | BMJ Open Diabetes Res Care |
|---|---|
| 主要な著者: | , , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
BMJ Publishing Group
2020
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7737050/ https://ncbi.nlm.nih.gov/pubmed/33318068 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/bmjdrc-2020-001649 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|